```
============================================================
```
Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2008; month=10; day=21; hr=12; min=59; sec=16; ms=72;]
```
============================================================
```

Application No: 10590548   Version No: 1.0

Input Set:

Output Set:

Started: 2008-09-18 18:41:51.347
Finished: 2008-09-18 18:41:52.296
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 949 ms
Total Warnings: 14
Total Errors: 0
No. of SeqIDs Defined: 14
Actual SeqID Count: 14

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)

<110>   CARLSSON, Anders
         BOGENTOFT, Conny
         STAHLE, Mona
         HEILBORN, Johan

<120>   NEW COMPLEXES

<130>   4528-0124PUS2

<140>   10590548
<141>   2008-09-18

<150>   PCT/SE05/00252
<151>   2005-02-23

<150>   US 60/546,966
<151>   2005-02-24

<150>   SE 0401942-8
<151>   2004-07-28

<160>   14

<170>   PatentIn version 3.5

<210>   1
<211>   37
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide LL-37

<400>   1

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val
            20   25   30

Pro Arg Thr Glu Ser
        35

<210>   2
<211>   36
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide LL-36

<400> 2

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val
            20   25   30

Pro Arg Thr Glu
        35

<210>   3
<211>   35
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide LL-35

<400>   3

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val
            20   25   30

Pro Arg Thr
        35

<210>   4
<211>   34
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic peptide LL-34

<400>   4

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val
            20   25   30

Pro Arg

<210> 5
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-33

<400> 5

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val
            20   25   30

Pro

<210> 6
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-32

<400> 6

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val
            20   25   30

<210> 7
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-31

<400> 7

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu

<210> 8
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-30

<400> 8

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn
            20   25   30

<210> 9
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-29

<400> 9

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg
            20   25

<210> 10
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-28

<400> 10

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu
            20   25

<210> 11
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-27

<400> 11

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe
            20   25

<210> 12
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-26

<400> 12

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys Asp
            20   25

<210> 13
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide LL-25

<400> 13

Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1   5   10   15

Phe Lys Arg Ile Val Gln Arg Ile Lys
            20   25

<210> 14
<211> 38
<212> PRT

```
Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1               5                   10                  15


Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val
            20                  25                  30


Pro Arg Thr Glu Ser Ser
        35
```